Bank of America: Resuming coverage of Eli Lilly and Co, rating it as 'Buy'.
Bank of America resumes coverage on Eli Lilly and Co, assigning a "Buy" rating with a Target Price of $997.
BofA Securities Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Cuts Target Price to $997
Eli Lilly and Co (LLY.US) seeks to expand the indications for its weight loss medication and will conduct trials to treat addictive behaviors.
Eli Lilly and Co will test a weight loss drug for treating addiction in 2025.
BofA Restarts Coverage of 11 Large-cap Biopharmas
Market Falls Wednesday, but Googles Chip Impresses | WST
Eli Lilly's $15 Billion Buyback Faces Stiff Resistance On The Charts
